The lacrimal glands are exposed to relatively high doses of radiation after [177Lu]Lu-PSMA-617 administration (31); thus, dry eye is considered a clinically relevant symptom in PSMA-targeted RPT and has been reported to be associated with higher treatment responses (19). Here, FOLH1 is linked to dry eye syndrome.